AbbVie

Phase 2 Study of Upadacitinib (RINVOQ) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

North Chicago, Illinois, US - 31 May 2023 - PRNewswire - AbbVie (NYSE: ABBV) today announced the results of the Phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg) alone and in combination [ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg)] in adults with moderately to severely active systemic lupus erythematosus (SLE) who...
AbbVie House Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

+44 (0) 1628 561090